IDEXX Laboratories (MEX:IDXX) Cyclically Adjusted Revenue per Share: MXN (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:IDXX IDEXX Laboratories Inc MEX:IDXX
95 GF Score
Price MXN8,917.00
GF Value MXN10,758.71
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is IDEXX Laboratories Cyclically Adjusted Revenue per Share?

IDEXX Laboratories MEX:IDXX 95 Cyclically Adjusted Revenue per Share is MXN as of Jun. 2026. GuruFocus rates MEX:IDXX with a GF Score™ of 95/100 and a GF Value™ of MXN10,758.71 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

IDEXX Laboratories's adjusted revenue per share for the three months ended in Jun. 2026 was MXN266.829. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is MXN for the trailing ten years ended in Jun. 2026.

During the past 12 months, IDEXX Laboratories's average Cyclically Adjusted Revenue Growth Rate was 11.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of IDEXX Laboratories was 16.30% per year. The lowest was 11.80% per year. And the median was 13.70% per year.

As of today (2026-09-22), IDEXX Laboratories's current stock price is MXN8917.00. IDEXX Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was MXN. IDEXX Laboratories's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 8.56. And the median was 14.78.


IDEXX Laboratories  (MEX:IDXX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of IDEXX Laboratories was 30.79. The lowest was 8.56. And the median was 14.78.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


IDEXX Laboratories Cyclically Adjusted Revenue per Share Related Terms


IDEXX Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for IDEXX Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDEXX Laboratories Cyclically Adjusted Revenue per Share Chart

IDEXX Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IDEXX Laboratories Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MEX:IDXX vs A, IQV, WAT: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, IDEXX Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDEXX Laboratories Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDEXX Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IDEXX Laboratories's Cyclically Adjusted PS Ratio falls into.


MEX:IDXX
95GF Score
IDEXX Laboratories Inc MEX:IDXX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDEXX Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IDEXX Laboratories's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=266.829/333.9520*333.9520
=266.829

Current CPI (Jun. 2026) = 333.9520.

IDEXX Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 92.264 241.428 127.623
201612 97.028 241.432 134.210
201703 104.230 243.801 142.771
201706 105.041 244.955 143.204
201709 98.294 246.819 132.994
201712 107.745 246.524 145.956
201803 113.225 249.554 151.517
201806 127.198 251.989 168.571
201809 117.047 252.439 154.842
201812 124.031 251.233 164.868
201903 126.346 254.202 165.984
201906 135.372 256.143 176.494
201909 134.164 256.759 174.500
201912 133.659 256.974 173.697
202003 144.803 258.115 187.348
202006 172.143 257.797 222.995
202009 184.043 260.280 236.136
202012 170.529 260.474 218.634
202103 182.147 264.877 229.648
202106 190.896 271.696 234.638
202109 187.642 274.310 228.440
202112 193.039 278.802 231.224
202203 200.480 287.504 232.869
202206 203.345 296.311 229.176
202209 202.567 296.808 227.917
202212 194.635 296.797 219.001
202303 200.037 301.836 221.321
202306 198.869 305.109 217.669
202309 186.014 307.789 201.826
202312 188.668 306.746 205.401
202403 195.132 312.332 208.639
202406 207.502 314.175 220.564
202409 222.342 315.301 235.494
202412 232.342 315.605 245.849
202503 248.746 319.799 259.754
202506 267.467 322.561 276.912
202509 255.261 324.800 262.454
202512 248.017 324.054 255.593
202603 249.904 330.213 252.734
202606 266.829 333.952 266.829

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of MXN mean?
IDEXX Laboratories (MEX:IDXX) has a Cyclically Adjusted Revenue per Share of MXN as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors.
Is IDEXX Laboratories' Cyclically Adjusted Revenue per Share too high?
IDEXX Laboratories' current Cyclically Adjusted Revenue per Share is MXN. Overall, IDEXX Laboratories has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDEXX Laboratories' Cyclically Adjusted Revenue per Share compare to A and IQV?
IDEXX Laboratories' Cyclically Adjusted Revenue per Share of MXN can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on IDEXX Laboratories and its competitors. IDEXX Laboratories's current Cyclically Adjusted Revenue per Share is MXN. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDEXX Laboratories stock overvalued right now?
Based on GuruFocus' analysis, IDEXX Laboratories (MEX:IDXX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN10,758.71, compared to a current price of MXN8,917.00 — trading 17.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is MXN. IDEXX Laboratories' overall GF Score™ is 95/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For IDEXX Laboratories (MEX:IDXX), the current Cyclically Adjusted Revenue per Share is MXN as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IDEXX Laboratories (MEX:IDXX) Overvalued in 2026?

Based on GuruFocus' analysis, IDEXX Laboratories stock appears to be undervalued. The current stock price of MXN8,917.00 is trading 17.1% below its estimated GF Value™ of MXN10,758.71. GuruFocus considers IDEXX Laboratories to be Modestly Undervalued.

Key valuation signals for MEX:IDXX:

  • Cyclically Adjusted Revenue per Share: MXN
  • GF Value™: MXN10,758.71 vs. price of MXN8,917.00 (17.1% below fair value)
  • GF Score™: 95/100 with 1 warning sign

No single metric tells the full story. See the MEX:IDXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDEXX Laboratories Business Description

Address One IDEXX Drive, Westbrook, ME, USA, 04092
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
95GF Score

Get the complete analysis for MEX:IDXX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN8,917.00
Price
MXN10,758.71
GF Value